Clay Siegall Boosts His Board Memberships

Biopharmaceutical company Mirna Therapeutics has signed on the co-founder, president, chief executive and chairman of biotech industry pioneer Seattle Genetics to its outside Board of Directors.

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

Clay Siegall joins board members Paul Lammers, M.D. M.Sc., president and chief executive officer, Mirna Therapeutics; Ed Mathers, partner, New Enterprise Associates; Matthew Winkler, Ph.D., founder and chairman, Asuragen and additional board members to facilitate advancements in broadening the company’s microRNA based therapeutics.

Lammers commented in a statement that the company is honored to have someone with Siegall’s expertise and background in cancer research on their board.

Founded in 2007, Mirna Therapeutics concentrates on microRNA in therapeutics. The clinical stage biopharmaceutical company is proceeding with microRNA-based oncology therapeutics and is the first to make a synthetic microRNA happen for the treatment of cancer.

Under the leadership of Siegall, a scientist by schooling with special importance on targeted cancer therapies, Seattle Genetics has put together a distinct set of anti-body cancer therapies by means of its industry leading technology for cancer patients whose medical needs were not being met.

The company has built up and made its antibody-drug conjugate (ADC) technology marketable over the years. ADCs are designed to target and destroy cancer cells only while sparing non-targeted cells and saving healthy cells.

Seattle Genetics has multiple strategic licenses for its ADC technology through partnership with companies such as AbbVie, Agensys, Bayer, Pfizer, Genentech (Roche) and others.

Siegall received a Ph.D. from George Washington University in genetics and worked for the National Cancer Institute and the National Institutes of Health after graduation.

He is Seattle Genetics board chairperson and his additional board memberships include Alder BioPharmaceuticals and Washington Biotech and BioMedical Association.

Siegall is also an author of more than 70 publications and holds 15 patents. He has received numerous awards including Alumnus of the Year for Computer, Math and Natural Sciences from the University of Maryland and the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012.

In addition, Siegall has led the company’s capital-raising activities, obtaining more than $330 million through public and private financing.